关于美国最近结束了二..干眼症领域或将出现一个专门针对睑板腺功能障碍(MGD)的药物。Azura公司实验中的新药AZR-MD-001于2022年末完成了二期临床测试,预计于今年三月开启第三轮临床测试。一直以来对于MDG的治疗
Methods : Adults with CLD and evidence of meibomian gland obstruction (n=67) were randomized (1:1) to AZR 0.5% (n=34) or vehicle (n=33) applied twice weekly at bedtime for 3 months in a Phase 2, multi-center, single-masked parallel-group study (NCT05548491). Key efficacy endpoints ...
Marc Gleeson, CEO of Azura, sat down with David Hutton, Managing Editor at Ophthalmology Times to discuss the recent positive results from the Phase 2 clinical trial of AZR-MD-001 in patients with contact lens discomfort. Video Transcript Editor's note ...
Methods : Adults with CLD and evidence of meibomian gland obstruction (n=67) were randomized (1:1) to AZR 0.5% ophthalmic ointment (n=34) or vehicle (n=33), applied to the lower lid twice weekly before bedtime for 3 months in a Phase 2, multi-center, double-masked parallel-group ...
Conclusions : AZR-MD-001 significantly improved signs of MGD and tear film stability in CLD beginning as early as 14 days (4 applications) with improvement to 3 months compared to vehicle. AZR-MD-001 demonstrated good efficacy, safety, and tolerability, with no significant adverse events ...
Methods : Adults with CLD and evidence of meibomian gland obstruction (n=67) were randomized (1:1) to AZR 0.5% ophthalmic ointment (n=34) or vehicle (n=33), applied to the lower lid twice weekly before bedtime for 3 months in a Phase 2, multi-center, double-masked parallel-group ...
AZR-MD-001 (AZR) selenium sulfide topical ointment was investigated as a treatment for MGD. Changes in tear film stability and symptoms of MGD were evaluated. Methods : In a Phase 2, 6-month, multicenter, double-masked, vehicle-controlled, parallel-group trial (NCT03652051), 245 adults were...
AZR-MD-001 Efficacy in Resolving the Signs and Associated Symptoms of Contact Lens Discomfort in a Phase 2 TrialPurpose : This study was designed to investigate whether treating the underlying cause of meibomian gland dysfunction (MGD) with AZR MD 001 (AZR) can open meibomian glands and improve...
Methods : Adults with mild to moderate MGD (n=245) were randomized (1:1:1) to AZR 0.5% (n=82) or 1.0% (n=83), or vehicle (n=80) applied by the subjects to the lower eyelid, twice weekly at bedtime for 6 months in a Phase 2, prospective, double-masked trial (NCT03652051)....
Conclusions : Over 6 months, a greater proportion of patients applying both concentrations of AZR-MD-001 demonstrated a clinically meaningful response, with normalization of their meibomian gland function, meibum secretions, and the resolution of disease symptomology.Julie Marie Schallhorn...